Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease

Tokuda, Yasutaka; Arakura, Fuyuko; Uhara, Hisashi

doi:10.1007/s10147-014-0686-2

Cited by 45 publications

(52 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tokuda et al . reviewed previous reports and retrospectively examined 22 patients with advanced EMPD who received FP . In their study, RR, mPFS and mOS were 59%, 5·2 months and 12 months, respectively.…”

Section: The Efficacy Of Chemotherapeutic Regimensmentioning

confidence: 99%

Single‐agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series

et al. 2019

View full text Add to dashboard Cite

Section: The Efficacy Of Chemotherapeutic Regimensmentioning

confidence: 99%

Single‐agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series

et al. 2019

View full text Add to dashboard Cite

“…Currently, there is no consensus regarding the optimal chemotherapeutic regimen for treatment of metastatic EMPD. Numerous case reports and small retrospective studies have documented the efficacies of several regimens, including low‐dose 5‐fluorouracil + cisplatin (FP), 5‐fluorouracil, epirubicin, carboplatin, vincristine and mitomycin (FECOM) combination, the docetaxel (DTX) + S‐1 regimen and the cisplatin, epirubicin and paclitaxel combination regimen . However, treatment outcomes of these are not necessarily satisfactory.…”

Section: Introductionmentioning

confidence: 99%

“…However, treatment outcomes of these are not necessarily satisfactory. While low‐dose FP and FECOM regimens show median progression‐free survival (PFS) of 5.2 and 6.5 months, respectively, both showed median overall survival (OS) of less than 1 year . Furthermore, patients undergoing treatment with these combination chemotherapies usually suffer from severe side‐effects and require repeated hospitalization.…”

Section: Introductionmentioning

confidence: 99%

Weekly docetaxel monotherapy for metastatic extramammary Paget’s disease: Retrospective single‐institute analysis

Nakamura

Tanese

Hirai

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Monthly docetaxel (DTX) monotherapy is the first‐line regimen that is preferably used for metastatic extramammary Paget’s disease (EMPD). However, the high‐dose DTX regimen frequently causes severe hematological adverse events (AE). To overcome such safety concerns, a weekly low‐dose DTX monotherapy has been proposed for use in the treatment of various cancer types. In this study, we aimed to evaluate the feasibility and efficacy of weekly DTX (25 mg/m2) monotherapy for metastatic EMPD by retrospectively analyzing the clinical courses of 14 patients treated with this regimen. Weekly DTX monotherapy was well tolerated and all patients completed the treatment schedule without treatment withdrawal, dose reduction or treatment‐related death. While five cases (35.7%) experienced hematological AE, their severity was mild. The response rate was 35.7% (5/14 cases), which included five partial responses. The mean progression‐free survival (PFS) and overall survival were 7.1 (95% confidence interval [CI], 5.1–9.1) and 26.4 months (95% CI, 16.7–36.1), respectively. Furthermore, the median PFS was 7.3 months (95% CI, 4.5–10.0) in patients aged 65 years and younger and 7.1 months (95% CI, 4.4–9.9) in patients older than 65 years. These results suggest that weekly DTX monotherapy may be a useful regimen that has a high treatment continuation rate with low levels of hematological toxicity, regardless of the patient’s age for metastatic EMPD.

show abstract

“…reported that the response rate of DOC was 58% in a 12‐case study. Additionally, Tokuda et al . reported that the response rate of 5‐fluorouracil (5‐FU) and cisplatin (FP therapy) was 59% in a 22‐case study.…”

Section: Discussionmentioning

confidence: 99%

Successful TS‐1 monotherapy as the second‐line treatment for advanced extramammary Paget's disease: A report of two cases

Kato

Hida

Yamashita

et al. 2017

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

There is no standard chemotherapeutic treatment for advanced extramammary Paget's disease, though the effectiveness of some chemotherapy regimens, including docetaxel, has been reported. In this report, we report that TS-1 monotherapy was effective in two patients with advanced extramammary Paget's disease after docetaxel treatment failure. TS-1 monotherapy may be useful as the second-line treatment for patients with advanced extramammary Paget's disease.

show abstract

Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget’s disease

Abstract: Although the number of cases is limited and there is a bias because cases without clinical effects are less likely to be reported, this regimen might be considered a relatively effective option for advanced EPD.

Cited by 45 publications

References 9 publications

Single‐agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series

Single‐agent taxane is useful in palliative chemotherapy for advanced extramammary Paget disease: a case series

Weekly docetaxel monotherapy for metastatic extramammary Paget’s disease: Retrospective single‐institute analysis

Successful TS‐1 monotherapy as the second‐line treatment for advanced extramammary Paget's disease: A report of two cases

Contact Info

Product

Resources

About